Exchange: NASDAQ·Updated 09:45 PM EDT
News
all
press releases
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE PR Newswire MIAMI, July 29, 2026 MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A.advised Entera Bio Ltd. (NASDAQ: ENTX), a...
PR Newswire
More News
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved upwards byread more...
Benzinga
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
Zacks
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus
DELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.
Zacks
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.
Stocktwits
Entera Bio (ENTX) to Release Earnings on Friday
Entera Bio (NASDAQ:ENTX) will be releasing its Q1 2026 earnings after the market closes on Friday, May 8. (View Earnings Report at...
MarketBeat
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
What is HC Wainwright's Estimate for Entera Bio Q1 Earnings?
Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...
MarketBeat
HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price
HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near
Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...
MarketBeat

Advertisement|Remove ads.